# Patrick Y. Wen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/patrick-y-wen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 90,083 |
| Field | Glioma Diagnosis and Treatment |
| h-index | 148 |
| i10-index | 678 |
| Last Known Institution | Dana-Farber Cancer Institute |
| OpenAlex ID | https://openalex.org/A5021656597 |
| ORCID iD | https://orcid.org/0000-0002-0774-7700 |
| Works | 1,915 |

## Researcher papers

Showing 12 of 14.

- [Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma](https://scholariq.org/papers/neoadjuvant-anti-pd-1-immunotherapy-promotes-a-survival-benefit-with/)
- [Bevacizumab for recurrent malignant gliomas](https://scholariq.org/papers/bevacizumab-for-recurrent-malignant-gliomas/)
- [Immunotherapy response assessment in neuro-oncology: a report of the RANO working group](https://scholariq.org/papers/immunotherapy-response-assessment-in-neuro-oncology-a-report-of-the-rano-working/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma](https://scholariq.org/papers/vorasidenib-in-idh1-or-idh2-mutant-low-grade-glioma/)
- [Mechanisms and therapeutic implications of hypermutation in gliomas](https://scholariq.org/papers/mechanisms-and-therapeutic-implications-of-hypermutation-in-gliomas/)
- [Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/central-nervous-system-cancers-version-3-2020-nccn-clinical-practice-guidelines/)
- [Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-brafv600e-mutated-biliary-tract/)
- [Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors](https://scholariq.org/papers/differential-sensitivity-of-glioma-versus-lung-cancer-specific-egfr-mutations-to/)
- [Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial](https://scholariq.org/papers/vorasidenib-a-dual-inhibitor-of-mutant-idh1-2-in-recurrent-or-progressive-glioma/)
- [Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma](https://scholariq.org/papers/randomized-phase-ii-and-biomarker-study-of-pembrolizumab-plus-bevacizumab-versus/)
- [NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017](https://scholariq.org/papers/nccn-guidelines-insights-central-nervous-system-cancers-version-1-2017/)

## Researcher topics

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)
- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)

## Researcher university

- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.